Aethlon Medical, Inc. (NASDAQ:AEMD – Get Free Report) saw a large decrease in short interest during the month of August. As of August 14th, there was short interest totaling 65,075 shares, a decrease of 71.9% from the July 30th total of 231,654 shares. Based on an average daily volume of 65,331 shares, the days-to-cover ratio is currently 1.0 days. Approximately 9.2% of the company’s stock are short sold.
Institutional Investors Weigh In On Aethlon Medical
A hedge fund recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in Aethlon Medical, Inc. (NASDAQ:AEMD – Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical at the end of the most recent reporting period. 1.99% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
AEMD has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Aethlon Medical to a “sell” rating in a report on Saturday, August 8th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.50 price objective on shares of Aethlon Medical in a research report on Tuesday, August 18th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a report on Friday, July 17th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $1.50.
Aethlon Medical Stock Down 4.8%
Shares of NASDAQ AEMD traded down $0.11 during trading on Thursday, reaching $2.17. 12,807,472 shares of the company traded hands, compared to its average volume of 102,264. The firm has a 50 day simple moving average of $3.68 and a 200-day simple moving average of $8.19. The stock has a market capitalization of $1.54 million, a PE ratio of -0.06 and a beta of 1.41. Aethlon Medical has a 52-week low of $2.17 and a 52-week high of $105.00.
Aethlon Medical (NASDAQ:AEMD – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share for the quarter, missing the consensus estimate of ($3.92) by ($0.10). As a group, research analysts predict that Aethlon Medical will post -5.74 EPS for the current year.
About Aethlon Medical
Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.
The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.
Featured Stories
- Five stocks we like better than Aethlon Medical
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
